Antileishmanial chemotherapy is hampered by the location of the parasite within the phagolysosome of the macrophage. This intracellular location restricts the activities of many putative antileishmanial drugs, which may be active against the extracellular promastigote but not against the intracellular amastigote. Allopurinol and allopurinol riboside are examples of such drugs; indeed, tested in vitro they are much more active against promastigotes (13, 19, 22) than against amastigotes (1, 4) . Allopurinol riboside is also of particular interest because, in the treatment of antimonialresistant visceral leishmaniasis, it can be used in combination with pentavalent antimony, suggesting a synergistic effect (8) . In contrast to allopurinol, antimonials are only effective against the intracellular form of the parasite, but they have no effect either on the promastigote stage or on free amastigotes (3, 14) . In addition, all drugs used in the chemotherapy of leishmaniasis, such as antimonials, amphotericin B, pentamidine, or methotrexate, are highly cytotoxic for most animal cells.
One way to solve both the bioavailability and the toxicity problems is to use drug delivery systems capable (i) of targeting specifically the drugs into macrophages in order to reduce the cytotoxicity of the drugs for noninfected cells and (ii) of releasing the active drug in close proximity to the parasite to increase the bioavailability of the drug. Various delivery systems have been described, including liposomes (2, 5, 20, 21) , niosomes (12), low-density lipoproteins (11), maleylated bovine serum albumin (7, 18) , or mannosylated bovine serum albumin (6) .
Macrophage surface carbohydrate-specific receptors (membrane lectins) induce the internalization of their ligands. It has been shown that elicited bone marrow-derived macrophages or alveolar macrophages have mannose and * Corresponding author. fucose receptors (26) which mediate the internalization of macromolecules bearing mannose and fucose residues in acidic endosomes where the ligand is released and are then carried into and degraded inside lysosomes (27) . Neoglycoproteins which are specifically endocytosed by macrophages via their membrane lectins have been developed (17) . By using mannosylated serum albumin as a carrier, it has been shown in in vitro experiments, that linked muramyl dipeptide (MDP) is at least 100 times more potent than free MDP for the activation of macrophages (16) and, in in vivo experiments, that the MDP conjugates were active while free MDP was not at all active (23) (24) (25) . It has also been shown (6) that methotrexate coupled to mannosylated bovine serum albumin is much more active than the free drug at killing the amastigotes of Leishmania donovani both in vitro and in vivo.
We have recently developed a new glycosylated carrier constituted of a poly-L-lysine (pLK) backbone, the e-amino groups of which are partially acylated by b-gluconolactone, while the others are substituted by carbohydrate residues and drugs. We have shown that this synthetic neutral carrier, which is easily prepared, highly soluble, biodegradable, and poorly immunogenic, is as efficient as neoglycoproteins at targeting drugs such as MDP (9) . The efficiency of the antiretroviral drug phosphonylmethoxyethyladenine in inhibiting the multiplication of herpes simplex virus type 1 in macrophages derived from blood monocytes was 50 times greater than that of the free drug when it was linked to this mannosylated polypeptide (15) . The absence of activity of mannose-free drug polymers is crucial in demonstrating that membrane lectins play a role in this specific targeting. This kind of synthetic polymer represents a carrier system which may be more generally useful for providing a stable and efficient drug delivery system to the macrophage.
The present study explored the feasibility of using this mannosylated polymer to target allopurinol riboside to L. donovani-infected macrophages via the mannose-fucose receptor.
MATERIALS AND METHODS
Chemicals. pLK, HBr (molecular weight, 30,000 to 50,000), containing about 190 lysine residues, and N4-t-butoxycarbonyl (Boc)-glycyl-glycine (N-Boc-Gly-Gly-OH) were Synthesis of the HPP-Rib and the inosine derivatives. The detailed synthesis of HPP-Rib and the inosine derivatives will be described elsewhere. Briefly, O-p-phenyl-isothiocyanate 5'-phosphodiester allopurinol riboside (HPP-Rib-5'-P-(p-NCS) was synthesized by reaction of HPP-Rib on p-nitrophenyl phosphodichloridate to give O-p-nitrophenyl 5'-phosphodiester allopurinol riboside (HPP-Rib-5'-P-cp-NO2). This product was then reduced to O-p-aminophenyl 5'-phosphodiester allopurinol riboside (HPP-Rib-5'-P-(p-NH2), which was further reacted with thiophosgene to give the phenylisothiocyanate 5'-phosphodiester derivative of HPP-Rib. The inosine derivative was synthesized in the same way, starting with inosine 2',3'-isopropylidene.
Synthesis of the glycosylated carners. Synthesis of the glycosylated carriers was achieved by substituting the e-amino groups of pLK with Na-Boc-Gly-Gly-OH before acylation with D-gluconic acid b-lactone and, finally, acetylation of the residual amino groups. Then, the Boc groups were removed and the a-amino groups of the glycyl-glycine spacer arm were substituted by O-p-phenyl isothiocyanate 5 '-phosphodiester allopurinol riboside or inosine derivatives. In the same way, mannose residues were coupled to the remaining a-amino groups by the carboxyl group of the p-(carboxymethyl)phenyl-a-D-mannopyranoside by the method of Derrien et al. (9) by using BOP reagent (instead of the classical DCC-HOBt coupling reagent), which allowed us to solubilize polymers in dimethyl sulfoxide, which is a better solvent for these macromolecules, and to reduce the coupling reaction time. Finally, the remaining amino groups were acetylated with acetic anhydride. The general formula of such a pLK conjugate substituted with w acetyl (Ac) and x gluconoyl (GlcA) residues and with y HPP-Rib and z mannosyl (Man) residues through a glycyl-glycine (GG) spacer arm is Acw-, (GlcA),-, (HPP-Rib-5'-P-wp-TC-GG) -, and (Man-GG)_-pLK, where w + x + y + z = 190, and is schematically shown in Fig. 1 .
Parasites. The Ethiopian strain of L. donovani (MHOM/ ET/OT/HU3; LV 9) was used throughout these studies. The parasite was maintained in vivo by subinoculation in the cotton rat (Sigmodon hispidus), an animal which develops unusually heavy infections with this parasite (10) . Amastigotes were prepared by grinding infected cotton rat liver slices in a mortar by using sterile sand and tissue culture medium (RPMI 1640 containing 10% fetal calf serum and gentamicin, 0.15 mg/ml). After separating the cell suspension from the sand and the coarse tissue debris by sedimentation, the amastigotes were cleaned up by two consecutive differential centrifugations (first at 500 rpm and then at 2,000 rpm). The resulting amastigote suspension was substantially free of infected macrophages, but it was still contaminated with small cellular debris and a small number of erythrocytes. Aclg-, GlcA100-, (Ac-GG),5-, (HPP-Rib-P-(p-TC-GG) 16 
RESULTS
Effects of Pentostam, HPP-Rib, and HPP-Rib derivatives on L. donovani amastigotes in mouse peritoneal macrophages. Neutral macromolecular conjugates bearing either HPP-Rib or inosine (IMP) were synthesized by coupling these derivatives to the e-groups of pLK through a glycyl-glycine spacer arm. The acylation of 50 to 60 pLK side chains by mannose residues allows the targeting of these conjugates into macrophages. We have previously demonstrated (9) that this amount of sugar residue allows a good internalization by macrophage membrane lectins. Gluconoylation and, finally, acetylation of the residual e-amino groups avoid nonspecific electrostatic interactions which could impair the specific binding and the receptor-mediated endocytosis. The macromolecular conjugates synthesized in this study are listed in Table 1 ; the drug concentrations in Table 1 are expressed as the relative amounts of free drug. These conjugates, u_p to 1.5 mg/ml, which corresponded to about 3 x 10-M therapeutic agent, did not induce any toxic effects on the macrophages.
The leishmanicidal activities of the conjugates synthesized in this study were checked after 3 or 7 days. The activities were determined in infected macrophages that were maintained in culture during this period with various amounts of polymer corresponding to 7.5 to 300 FM drug ( Fig. 2A and  B ). An equivalent amount of mannosylated polymer without any drug was used to check the absence of activity of the carrier itself. Inosine, an analog of HPP-Rib devoid of leishmanicidal activity, was coupled to the carrier in the same way as HPP-Rib was to ascertain the specificity of the leishmanicidal activity. After 3 days ( Fig. 2A) , HPP-Rib free or coupled to pLK alone (HPP-Rib-pLK) had practically no effect up to 3 x 10-4 M, while HPP-Rib-pLK-Man killed 50% of the amastigotes at this highest concentration. Pentostam, which was used as a therapeutic reference compound, was slightly more active than HPP-Rib-pLK-Man. After 7 days (Fig. 2B) , the targeted HPP-Rib was still efficient at a concentration of as low as 37 ,uM, which gave 70% leishmanicidal activity. This crucial experiment gave consistently similar results when it was repeated five times with different levels of cell infection (data not shown). Free HPP-Rib or HPP-Rib bound to mannose-free polymer had the same low activity: a 40% leishmanicidal effect at 300 FiM.
Targeting by mannosylated polymers specifically internalized by macrophage membrane lectins clearly increased the efficiency of antileishmanial drug. This activity was not due to the carrier, since pLK-Man or IMP-pLK-Man did not induce any reduction in the number of amastigotes.
DISCUSSION
In the in vitro experiments described here, we examined a novel method for drug delivery. A leishmanicidal drug, HPP-Rib, was linked to a macromolecular carrier targeted to the mannose-fucose receptor of macrophages by means of mannosyl residues. This conjugate and control derivatives (HPP-Rib, free or bound to the nontargeted polymer) were tested in L. donovani-infected macrophages. Because the development of amastigotes occurs exclusively within the phagolysosomes of macrophages, the mannose lectin is a privileged target because it is located at the surface of the macrophage and allows specific internalization of mannosylated ligands which are quickly transferred from endocytic vesicles to early endosomes (where receptor-ligand dissociation occurs) and then to the phagolysosomes.
Gluconoylated pLK as a carrier has the advantages of being very soluble, is easily prepared because all reactions can be conducted in organic solvent, is barely immunogenic, is biodegradable, and is nontoxic even at high doses (9) . When mannosylated, these conjugates are readily internalized by macrophage membrane lectins.
The 50% effective dose of HPP-Rib linked to the mannosylated polylysine was less than 7.5 x 10-6 M, while it was up to 3 x 10' M for the free HPP-Rib. This result shows that HPP-Rib bound to the polymer is 50 times more active than the free drug at killing the parasites. The results described in Fig. 2 show that the HPP-Ribmannosylated polymer conjugate is much more effective that the HPP-Rib-free polymer conjugate, indicating that the enhancement of the antileishmanial effect of HPP-Rib is mostly achieved by means of the mannose homing device. The partial activity of the HPP-Rib-mannose-free polymer conjugate may be due to the presence of phosphodiesterase in the culture medium, releasing free HPP-Rib in the proximity of the macrophage.
Furthermore, the observation that the mannosylated drugfree polymer and the inosine derivatives have no activity when internalized by macrophages, even at the highest concentration, excludes the hypothesis that the carrier, including the mannose residues and the drug-carrier linkage, has antiparasitic activity.
In the in vitro experiments described here, the antileishmanial effect of the HPP-Rib conjugate was less pronounced that the effect of Pentostam, the "gold standard" in leishmanial chemotherapy, but it should be noted that the polymeric conjugate showed no toxicity at any concentration used.
This type of neutral, biodegradable, nontoxic and nonimmunogenic mannosylated polymer is a good system for carrying antileishmanial drugs to leishmania-infected macrophages via the mannose-fucose receptor of the macrophages. It is worth pointing out, however, that while the results obtained in the study described here confirm the feasibility of this novel method for drug targeting, there may be a long way from the experimental design to clinical applications; for instance, liposome-encapsulated antimonials were first described in 1978 (21), but they are only now available for clinical trials. While HPP-Rib was selected in this preliminary trial because of its poor activity against intracellular amastigotes, this delivery system could clearly be used in vivo to increase the bioavailability and/or to reduce the toxicity of more powerful antileishmanial compounds, as long as their chemical characteristics allow coupling to the carrier.
More generally, the polymers described here may be suitable for the targeting of a variety of drugs to macrophages and may be adapted for targeting to other cell types by changing the homing device.
